Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas

Annals of Hematology

Volumn 85, Issue 9, 2006, Pages 575-581

  Jung, Jin Tae ^a   Kim, Dong Hwan ^a   Kwak, Eun Kyung ^a   Kim, Jong Gwang ^a   Park, Tae In ^a   Sohn, Sang Kyun ^a   Do, Young Rok ^b   Kwon, Ki Young ^b   Song, Hong Suk ^b   Park, Eui Hyun ^a   Lee, Kyu Bo ^a  

^a Kyungpook National University Hospital   (South Korea)

^b Keimyung University   (South Korea)

Author keywords

Apoptosis related gene; Bcl 2; p53; Peripheral T cell lymphomas

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; PARAFFIN; PREDNISONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; PSORALEN; VINCRISTINE;

ADULT; AGED; ANAPLASTIC CARCINOMA; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PUVA; SKIN LYMPHOMA; T CELL LYMPHOMA;

ADULT; AGED; BCL-2-ASSOCIATED X PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33747868748     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0127-z     Document Type: Article

References (25)

1. Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21:485-495
2. Chen-Levy Z, Nourse J, Cleary ML (1989) The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t (14;18) translocation. Mol Cell Biol 9:701-710
3. Aisenberg AC, Wilkes BM, Jacobson JO (1988) The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood 71:969-972
4. Raghoebier S, van Krieken JH, Kluin-Nelemans JC, Gillis A, van Ommen GJ, Ginsberg AM, Raffeld M, Kluin PM (1991) Oncogene rearrangements in chronic B-cell leukemia. Blood 77:1560-1564
5. Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M (1996) Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer 69:114-119
6. Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aime-Sempe C, Bodrug S, Kitada S, Hanada M (1996) BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60:23-32
7. Wang Y, Okan I, Szekely L, Klein G, Wiman KG (1995) bcl-2 inhibits wild-type p53-triggered apoptosis but not G1 cell cycle arrest and transactivation of WAF1 and bax. Cell Growth Differ 6:1071-1075
8. Chiou SK, Rao L, White E (1994) Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 14:2556-2563
9. Rassidakis GZ, Jones D, Lai R, Ramalingam P, Sarris AH, McDonnell TJ, Medeiros LJ (2003) BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation. J Pathol 200:240-248
10. Pescarmona E, Pignoloni P, Puopolo M, Martelli M, Addesso M, Guglielmi C, Baroni CD (2001) p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome. J Pathol 195:361-366
11. Gascoyne RD, Krajewska M, Krajewski S, Connors JM, Reed JC (1997) Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:3173-3178
12. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P, Coldman AJ, Reed JC, Connors JM (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244-251
13. Sohn SK, Jung JT, Kim DH, Kim JG, Kwak EK, Park T, Shin DG, Sohn KR, Lee KB (2003) Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. Am J Hematol 73:101-107
14. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849
15. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479
16. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F, Gaulard P (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87:265-272
17. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, de Jong D, Maartense E, Schuuring E, Kluin PM (1998) Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92:3152-3162
18. ten Berge RL, Meijer CJ, Dukers DF, Kummer JA, Bladergroen BA, Vos W, Hack CE, Ossenkoppele GJ, Oudejans JJ (2002) Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 99:4540-4546
19. Villalva C, Bougrine F, Delsol G, Brousset P (2001) Bcl-2 expression in anaplastic large cell lymphoma. Am J Pathol 158:1889-1890
20. Nevala H, Karenko L, Vakeva L, Ranki A (2001) Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. Br J Dermatol 145:928-937
21. Osada M, Ishioka C, Ichinohasama R, Kadowaki I, Murakawa Y, Watanabe M, Kanamaru R, Ikawa S (1999) Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphoma. Anticancer Drug Dis 14:107-114
22. Kramer MH, Hermans J, Parker J, Krol AD, Kluin-Nelemans JC, Haak HL, van Groningen K, van Krieken JH, de Jong D, Kluin PM (1996) Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study. J Clin Oncol 14:2131-2138
23. Korkolopoulou P, Angelopoulou MK, Kontopidou F, Tsenga A, Patsouris E, Thomas-Tsagli E, Kittas C, Pangalis GA (1998) Prognostic relevance of apoptotic cell death in non-Hodgkin's lymphomas: A multivariate survival analysis including Ki67 and p53 oncoprotein expression. Histopathology 33:240-247
24. Ichikawa A, Hotta T, Saito H (1993) Mutations of the p53 gene in B-cell lymphoma. Leuk Lymphoma 11:21-25
25. Piris MA, Pezzella F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuena R, Cruz MA, Martinez B, Pezella F, et al. (1994) p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time. Br J Cancer 69:337-341